Currently, PD-L1 tumour tissue scoring is used clinically to determine likelihood of response to therapy, however this has shown to have limitations in determining cutoff for PD-L1 positivity reflecting the dynamic nature of PD-L1 as a biomarker [7,8]. Here, CD274 is linked to neoplasm.